ONWARD Medical, a Dutch neurotechnology pioneer based in Eindhoven, has secured €40.6 million in funding to accelerate development of its groundbreaking spinal cord stimulation technology. The capital infusion marks a significant milestone for the company as it pursues regulatory approval for a therapy designed to restore blood pressure control in spinal cord injury patients—a condition that currently affects thousands worldwide with limited treatment options.
What Happened
The funding will primarily support ONWARD Medical’s Empower BP pivotal clinical trial, which is evaluating whether the company’s implantable ARC-IM® system can effectively treat orthostatic hypotension and other blood pressure irregularities in spinal cord injury patients. The proceeds will also fuel commercial expansion of its ARC-EX® external therapy system, which has already cleared regulatory pathways in key markets. With this capital injection, the company has extended its operational runway through the first quarter of 2028, providing crucial time to complete clinical validation and scale manufacturing operations.
Key Details
The investment reflects growing confidence from institutional backers in ONWARD Medical’s dual-track approach: advancing next-generation implantable devices while commercializing existing cleared technologies. The ARC-IM® system represents a next frontier in neuromodulation, targeting a complication of spinal cord injury that dramatically impacts patient quality of life and independence. Blood pressure instability following spinal cord injury can lead to dangerous fluctuations, limiting physical activity and rehabilitation potential. The ARC-EX® system, already available in select markets, offers a non-implantable alternative for external spinal cord stimulation therapy. This portfolio strategy positions the company to generate near-term revenue while pursuing longer-term high-impact innovations.
What This Means for You
For spinal cord injury patients and their families, ONWARD Medical’s progress represents tangible hope for improved treatment options and better quality of life. The company’s focus on physiological restoration rather than merely symptomatic management addresses a genuine unmet medical need. For investors monitoring the neurotech sector, this funding round underscores the substantial capital requirements and extended timelines inherent in bringing medical devices to market, while also demonstrating investor appetite for solutions targeting serious neurological conditions.
As ONWARD Medical advances toward pivotal trial completion, the company stands at an inflection point in the neurotechnology landscape. Successful clinical validation of the ARC-IM® system could establish a new treatment category while validating the broader potential of targeted neuromodulation for spinal cord injuries. The next 18-24 months will be critical for demonstrating efficacy and safety—outcomes that could reshape treatment paradigms for thousands of patients globally.
